Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Leases: 2020-2024

Historic Current Leases for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $9.1 million.

  • Foghorn Therapeutics' Current Leases fell 22.98% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 22.98%. This contributed to the annual value of $9.1 million for FY2024, which is 6.45% up from last year.
  • Foghorn Therapeutics' Current Leases amounted to $9.1 million in FY2024, which was up 6.45% from $8.5 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Current Leases ranged from a high of $9.1 million in FY2024 and a low of $4.0 million during FY2020.
  • In the last 3 years, Foghorn Therapeutics' Current Leases had a median value of $8.5 million in 2023 and averaged $7.9 million.
  • In the last 5 years, Foghorn Therapeutics' Current Leases surged by 75.68% in 2021 and then decreased by 14.64% in 2022.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Current Leases stood at $4.0 million in 2020, then surged by 75.68% to $7.0 million in 2021, then fell by 14.64% to $6.0 million in 2022, then spiked by 42.68% to $8.5 million in 2023, then increased by 6.45% to $9.1 million in 2024.